India Glycols Shareholders Overwhelmingly Approve Demerger Plan

Shareholders of India Glycols Limited have overwhelmingly approved a plan to demerge its spirits and biopharma businesses into separate companies, following an order from the National Company Law Tribunal (NCLT). The resolution passed with a near-unanimous vote of 4,42,48,625 in favour out of 4,42,48,626 total votes cast.

What Investors Should Know

Shareholders have strongly backed the demerger plan. The next critical step is final approval from the NCLT to unlock value.

Shareholder Vote Details

India Glycols Limited shareholders met on March 24, 2026, to vote on the demerger plan, as directed by the National Company Law Tribunal (NCLT) in Allahabad. The plan involves separating India Glycols Limited (the 'Demerged Company') from its wholly-owned subsidiaries, Ennature Bio Pharma Limited and IGL Spirits Limited. The high turnout and overwhelming vote signal strong confidence in the company's restructuring strategy.

Strategic Rationale for Demerger

This approval is a crucial step for India Glycols to separate its various business units. The demerger aims to unlock value by creating distinct entities for its spirits, biofuel, and biopharma operations, enabling each to pursue focused growth strategies and attract specialized investors. This separation is expected to improve management, resource allocation, and capital efficiency for each business.

Company and Demerger Background

India Glycols Limited, known for its green petrochemicals, has been exploring restructuring to unlock value from its operations. Ennature Bio Pharma is its natural ingredients division, specializing in plant-based active pharmaceutical ingredients and nutraceuticals. IGL Spirits Limited, established in November 2024, will manage the company's spirits and biofuel business. The company's Board had previously approved a modified demerger plan on May 16, 2025. The current plan separates the spirits and biofuel operations into IGL Spirits and the biopharma operations into Ennature Bio Pharma. This trend of demergers is growing among Indian companies, with firms like Tata Motors, ITC, and Vedanta also splitting businesses to sharpen focus and boost shareholder value.

Impact on Shareholders

With shareholder approval, the demerger plan is now closer to being implemented. Shareholders will retain their stakes in India Glycols, which will continue to operate its bio-based specialties and performance chemicals business. The two new companies, IGL Spirits and Ennature Bio Pharma, are expected to be listed separately, providing investors with distinct investment opportunities.

Remaining Hurdles

While shareholder approval is a significant step, the demerger plan still requires final sanction from the National Company Law Tribunal (NCLT) and other regulatory bodies. The Securities and Exchange Board of India (SEBI) had previously provided comments, requiring the company to comply with specific regulations, including disclosures on ongoing legal proceedings.

Similar Industry Moves

Several Indian companies have recently undertaken demergers to unlock value and sharpen business focus. Examples include Tata Motors separating its passenger and commercial vehicle units, ITC demerging its hotel division, and DCM Shriram planning to split its chemicals and rayon businesses. These actions aim to create focused entities for independent growth and valuation.

Demerger Ratios and Contribution

• The Spirits and Biofuel segment accounted for 78.15% of the company's turnover in FY 23-24, while the Biopharma segment contributed 3.16%.
• The demerger plan includes an equity share issuance ratio of 1:1 for IGL Spirits Limited and one share in Ennature Bio Pharma for every three equity shares held in India Glycols Limited.

Future Steps

Investors will be closely watching for the final sanctioning order from the NCLT for the demerger plan. Following NCLT approval, the next steps involve the formal listing of IGL Spirits Limited and Ennature Bio Pharma Limited shares on stock exchanges, pending regulatory approvals. Adhering to SEBI and exchange regulations for listing the new companies will be essential.